Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2869159 | 0.87 | NPSR1 (0.35) | NPSR1TSHRALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL2863463 | 0.86 | NPSR1 (0.35) | NPSR1TSHRALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL2869730 | 0.85 | SIGMAR1 (0.43) | NPSR1TSHRALDH1A1ALOX15 | |
| SCHEMBL2864887 | 0.84 | NPSR1 (0.35) | NPSR1ALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL2868400 | 0.81 | OPRL1 (0.37) | NPSR1TSHRALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL2864536 | 0.81 | MC4R (0.46) | NPSR1ALDH1A1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL2863761 | 0.81 | NPSR1 (0.40) | NPSR1ALDH1A1TNKS | |
| Hydrochloric Acid SCHEMBL2860814 | 0.80 | NPSR1 (0.37) | NPSR1ALDH1A1CYP2C19 | |
| SCHEMBL2860998 | 0.80 | NPSR1 (0.41) | NPSR1TSHR | |
| SCHEMBL2864640 | 0.79 | NPSR1 (0.38) | NPSR1TSHRMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885TSHR 124/4885ALDH1A1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.